(Reuters) -Biogen and Sage Therapeutics do not plan to conduct further studies for their neurological disorder drug after it failed in a mid-stage trial, the drugmakers said on Wednesday.
The experimental drug, SAGE-324, was being studied as a treatment for essential tremor, a disorder that causes uncontrollable shaking of the hands, arms and other body parts.
The drug failed to show statistically significant dose-response relationship, as measured on a scale, for upper limb tremor.
The companies said they were planning the next steps, if any, to study the drug in other potential conditions.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)
Comments